ARS Pharmaceuticals Inc (NASDAQ:SPRY) price on current trading day, rose 8.19% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.34.
A look at the stock’s price movement, the close in the last trading session was $12.33, moving within a range at $11.8 and $13.68. The beta value (5-Year monthly) was 0.979 while the PE ratio in trailing twelve months stood at 173.92. Turning to its 52-week performance, $18.51 and $7.55 were the 52-week high and 52-week low respectively. Overall, SPRY moved 15.70% over the past month.
ARS Pharmaceuticals Inc’s market cap currently stands at around $1.31 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-19.
Analysts have a consensus estimate of 7.48M for the company’s revenue for the quarter, with a low and high estimate of 5M and 8.5M respectively. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 83.08M, representing a -6.80% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SPRY is a 100% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend SPRY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 3.96, with SPRY’s current price about 5.99% and 10.89% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.76, while 7-day volatility ratio is 12.36% and 8.61% in the 30-day chart. Further, ARS Pharmaceuticals Inc (SPRY) has a beta value of 0.77, and an average true range (ATR) of 1.07. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $18 and high of $30. Looking at the price targets, the low is -34.93% off current price level while to achieve the yearly target high, price needs to move -124.89%. Nonetheless, investors will most likely welcome a -64.92% jump to $22 which is the analysts’ median price.
If we refocus on ARS Pharmaceuticals Inc (NASDAQ:SPRY), historical trading data shows that trading volumes averaged 2.08 over the past 10 days and 1.65 million over the past 3 months. The company’s latest data on shares outstanding shows there are 97.95 million shares.
The 42.88% of ARS Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 50.12% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 19.43 million on 2025-03-14, giving us a short ratio of 15.06. The data shows that as of 2025-03-14 short interest in ARS Pharmaceuticals Inc (SPRY) stood at 3704.0 of shares outstanding, with shares short rising to 16.48 million registered in 2025-02-14. Current price change has pushed the stock 26.45% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SPRY stock continues to rise going into the next quarter.
